Covaxin neutralizes double mutant strain In India: Research Body ICMR
The ICMR study highlights that Covaxin is effective against the UK variants as well as other strains of Covid-19.
The Indian Council of Medical Research (ICMR) on Wednesday said that Bharat Biotech-ICMR’s COVAXIN is effective in neutralizing the multiple variants of SARS-Cov-2 as well as the double mutant strain that has been found in India.
Made in-India Covaxin has received Emergency Use Authorizations (EUAs) for COVID-19 treatment in India and in several countries across the world with another 60 in the process.
"ICMR study shows Covaxin neutralizes multiple variants of SARS-CoV-2 and effectively neutralizes the double mutant strain as well," the ICMR tweeted.
The study, which was published in the Journal for Travel Medicine in March, highlights that Covaxin is effective against the UK variants as well as other strains of Covid-19.
“It was reassuring from the PRNT50 data generated in our laboratory that the indigenous BBV152/ COVAXIN, following its roll out in vaccination program, could be expected to work against the new UK-variant,” the study said.
In its study, ICMR pointed out that the vaccine made by the Hyderabad-based pharmaceutical company is also effective against other variants like the Brazil variant as well the double mutant variant that has been detected in India.
It further said that ICMR has successfully cultured and isolated several variants of SARS-Cov-2.
The study noted that it has isolated and cultured the following variants of SARS-Cov-2 -- B.1.617 (double mutant variant identified in certain regions of India and several other countries), B.1.1.7 (UK variant), B.1.1.28 (Brazil variant), and B.1.351 (Southern African variant).
Covaxin along with Covishield and Sputnik V have been approved by the Centre for vaccinating individuals against the coronavirus disease.